» Articles » PMID: 7735558

Correlation of P-glycoprotein Detection by Immunohistochemistry with Mdr-1 MRNA Levels in Osteosarcomas. Pilot Study

Overview
Date 1995 Mar 1
PMID 7735558
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

All the factors that influence prognosis in patients with osteosarcomas have not been fully determined. One reported predictor of poor outcome is increased multi-drug resistant gene (mdr-1) expression, as measured by reverse transcription and polymerase chain reaction (RT-PCR). We examined whether immunostaining for p-glycoprotein, the protein product of mdr-1, could be used instead of RT-PCR to indicate the presence of the multidrug-resistant phenotype. The sensitivity of the immunostaining was determined using KB cell sublines. For 13 cases of osteosarcoma, samples were immunostained for p-glycoprotein and the levels of mdr-1 expression quantitated with use of RT-PCR. Three osteosarcomas with undetectable levels of mdr-1 expression by RT-PCR were negative immunohistochemically. Ten cases showed mdr-1 expression ranging from approximately 1 to 32 copies of mdr-1 mRNA/cell. Of these cases, five cases contained occasional tumour cells with positive immunostaining. There was no correlation between levels of expression and the presence or number of immunoreactive cells. These results indicate that the presence of p-glycoprotein immunostaining does not reliably correlate with the level of mdr-1 expression. However it may be useful in conjunction with RT-PCR to further define different subgroups of osteosarcomas that may have different prognoses, and this is currently under investigation.

Citing Articles

Lipid-functionalized dextran nanosystems to overcome multidrug resistance in cancer: a pilot study.

Kobayashi E, Iyer A, Hornicek F, Amiji M, Duan Z Clin Orthop Relat Res. 2012; 471(3):915-25.

PMID: 23011844 PMC: 3563790. DOI: 10.1007/s11999-012-2610-2.


Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation.

Sorensen F, Jensen K, Vaeth M, Hager H, Funder A, Safwat A Sarcoma. 2009; 2008:874075.

PMID: 19266050 PMC: 2650184. DOI: 10.1155/2008/874075.


P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma.

Shnyder S, Hayes A, Pringle J, Archer C Br J Cancer. 1998; 78(6):757-9.

PMID: 9743295 PMC: 2062957. DOI: 10.1038/bjc.1998.573.


Expression of MDR1/p-glycoprotein and multidrug resistance-associated protein in childhood solid tumours.

Oda Y, Rose I, RADIG K, Wagemann W, Mittler U, Roessner A Virchows Arch. 1997; 430(2):99-105.

PMID: 9083512 DOI: 10.1007/BF01008030.


Quantitative analysis of multidrug resistance gene expression in human osteosarcomas.

Lee P, Noble-Topham S, Bell R, Andrulis I Br J Cancer. 1996; 74(7):1046-50.

PMID: 8855972 PMC: 2077112. DOI: 10.1038/bjc.1996.487.